Stockreport

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal [Yahoo! Finance]

Amicus Therapeutics, Inc.  (FOLD) 
Last amicus therapeutics, inc. earnings: 11/11 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.amicusrx.com/investor-relations
PDF study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. The ROSEL [Read more]